AUPH — Aurinia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.23bn
- $1.84bn
- $283.06m
Aurinia Pharmaceuticals Inc expected to post earnings of 2 cents a share - Earnings Preview
Brief: Aurinia Announces Japan Approval Of Lupkynis (Voclosporin) To Treat Lupus Nephritis
Aurinia Pharmaceuticals jumps after Tang Capital reports 5.1% stake in co
Brief: Tang Capital Management Reports 5.1% Stake In Aurinia Pharmaceuticals Inc As Of September 6 - SEC Filing
Brief: Aurinia Announces Board Restructuring
Brief: Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
Brief: Lucien Selce Calls For CEO Peter Greenleaf, Brinda Balakrishnan, Robert Foster To Resign From Aurinia Pharmaceuticals Board
Brief: Aurinia Pharmaceuticals Q2 Product Revenue USD 55.028 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 1 cent a share - Earnings Preview
Brief: Iljin Snt Co Ltd Announces Intention To Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal
Brief: Aurinia Addresses Dubious Proposals Put Forth By Lucien Selce
Brief: Aurinia To Attend 2024 Jefferies Global Healthcare Conference
Brief: Aurinia Presents Data Reinforcing Lupkynis® Safety And Efficacy For People With Lupus Nephritis At Congress Of Clinical Rheumatology East 2024
Brief: Lucien Selce Issued Letter To Aurinia Shareholders
Brief: Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Aurinia Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Aurinia Pharmaceuticals Q1 EPS USD -0.07
Brief: Aurinia Underscores Enduring Commitment To People Living With Lupus Nephritis Through Innovative Advocacy And Education Initiatives
Brief: Aurinia Pharmaceuticals Says FDA Has Approved A Label Update For Lupkynis